Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 10Myelodysplastic Syndromes 3Congenital Abnormalities 2Rectal Neoplasms 1Leukemia 1

Interventions

Cyclophosphamide 52Cytarabine 49fludarabine phosphate 38fludarabine 32Filgrastim 30Etoposide 23Rituximab 19Azacitidine 17Whole-Body Irradiation 16Tacrolimus 14Peripheral Blood Stem Cell Transplantation 13Granulocyte Colony-Stimulating Factor 13Decitabine 13Clofarabine 13venetoclax 12Melphalan 12Antilymphocyte Serum 12Mycophenolic Acid 11Methotrexate 11Radiotherapy 10Mitoxantrone 10Daunorubicin 10Busulfan 10sargramostim 9aldesleukin 9Vincristine 9Sirolimus 9Topotecan 8Idarubicin 8Dexamethasone 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia × midostaurin × Clear all
NCT06313437 2026-03-25

Revumenib in Combination With 7+3 + Midostaurin in AML

Dana-Farber Cancer Institute

Phase 1 Recruiting
22 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡